|
|
|
Dear [fullname,fallback=Recipient's name],
|
|
Please join us for the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs.
|
|
Dr. Aaron B. Waxman will review the latest developments from the AHA Scientific Sessions 2020 for sotatercept—an investigational agent being studied in clinical trials that may address a key driver of
PAH progression. He will discuss how this potential therapy aims to rebalance BMPR2 signaling and explain the importance of this mechanistic direction.
|
|
A Potential Therapy for Rebalancing BMPR2:
|
|
A New Direction in PAH
|
|
|
|
Featuring Aaron B. Waxman, MD, PhD
|
Saturday, February 27th at 3:05 PM CET (9:05 AM ET)
followed by a virtual Q&A session
|
|
Topic overview
|
|
Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on
the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression, reviewing the latest data available.
A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.
|
|
|
Attend the 9th International Meeting on Pulmonary Rare Diseases
and Orphan Drugs!
|
|
|
Once registered, a confirmation email with a username and password to access the web platform
will be sent to you.
|
|
|
Acceleron is passionate about accelerating the discovery of novel therapies that can help patients with PAH and other rare diseases. We hope you find this presentation helpful as we look to the future of PAH therapy.
|
|
|
Sotatercept is an investigational therapy that is not approved for any use in any country. The safety and efficacy of sotatercept have not been established.
|
|
This message was sent by Acceleron Pharma Inc.
|
|
|
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
www.acceleronpharma.com
|
|
©2021 Acceleron Pharma Inc.
|
|
All rights reserved.
|
|
Acceleron Pharma Inc.
|
|
Privacy Notice
|
|
Community Guidelines
|
|
Unsubscribe
|
|